# A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

> **NCT00715403** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 41 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT00715403
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00715403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00715403, "A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00715403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*